Tecentriq: Regulatory submissions in Japan for ovarian cancer, muscle-invasive urothelial cancer (adjuvant) and hepatocellular cancer in 2020 (Chugai) - Oct 25, 2019 - Q3 2019 Results: Regulatory submissions in Japan for early breast cancer and NSCLC (neoadjuvant) in 2021
Japanese regulatory
|